Vaxart early-stage trial shows immune response of norovirus vaccine candidate in elderly
seekingalpha.com
finance
2022-06-02 13:20:36

Jun. 02, 2022 9:20 AM ETVaxart, Inc. (VXRT)By: Anuron Mitra, SA News Editor jarun011/iStock via Getty Images Vaxart (NASDAQ:VXRT) on Thursday reported what it deemed to positive preliminary data from its phase 1b trial of its oral norovirus vaccine candidate in adults aged 55-80 years. VXRT stock +1.2% to $3.49 in premarket trading. The vaccine candidate targets the norovirus, a very contagious virus that causes vomiting and diarrhea. Results of the early stage trial support the safety and immunogenicity of the candidate in the highly vulnerable elderly population.
